@phdthesis{Heinemann2023,
  author    = {Heinemann, Hannes},
  title     = {Lebensqualit{\"a}t und Coping beim Multiplen Myelom},
  doi       = {10.25972/OPUS-31322},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-313227},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Einf{\"u}hrung: Beim Multiplen Myleom handelt es sich um eine b{\"o}sartige Proliferation der Plasmazellen, wenn es auch nur 1\% aller b{\"o}sartigen Erkrankungen ausmacht, muss angesichts der steigenden Lebenserwartung von einer Zunahme der F{\"a}lle ausgegangen werden. Methoden: Diese Dissertation soll als {\"U}bersichtsarbeit zur QoL und Coping bei MM-Patienten und deren Angeh{\"o}rigen dienen. Es konnten 101 relevante Studien in der Literaturrecherche gefunden werden. Resultate: In allen Bereichen lag bei MM-Patienten, abgesehen von fr{\"u}hen Stadien oder bei Patienten mit CR, eine schlechtere QoL als bei der Referenzpopulation vor. Diese Ergebnisse waren unabh{\"a}ngig vom verwendeten QoL-Erhebungsinstrument. Vor allem die Tatsache, dass Multiples Myleom unheilbar ist, ist f{\"u}r die Patienten sehr belastend. Es lagen die unterschiedlichsten Coping-Mechanismen bei den Patienten und deren Angeh{\"o}rigen vor. Soziale Unterst{\"u}tzung war meistens der QoL f{\"o}rderlich, wenn es auch problematische Formen gab. Es konnten diverse, teils widerspr{\"u}chliche Korrelationen von QoL und demographischen Faktoren, wie Alter und Geschlecht gefunden werden. Diskussion: Auch wenn in den letzten Jahren vermehrt in diesem Gebiet geforscht wurde, gestaltete es sich als schwierig Studien zu dem Thema zu finden und es bleibt zu hoffen, dass zuk{\"u}nftig ein gr{\"o}ßerer Fokus hier gelegt wird.},
  subject      = {Plasmozytom},
  language  = {de}
}
@article{LiPamporakiFliedneretal.2021,
  author    = {Li, Minghao and Pamporaki, Christina and Fliedner, Stephanie M. J. and Timmers, Henri J. L. M. and N{\"o}lting, Svenja and Beuschlein, Felix and Prejbisz, Aleksander and Remde, Hanna and Robledo, Mercedes and Bornstein, Stefan R. and Lenders, Jacques W. M. and Eisenhofer, Graeme and Bechmann, Nicole},
  title     = {Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion},
  series = {Discover Oncology},
  volume    = {12},
  journal   = {Discover Oncology},
  issn      = {2730-6011},
  doi       = {10.1007/s12672-021-00404-x},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-309901},
  year      = {2021},
  abstract  = {Background The presence or future development of metastatic pheochromocytomas or paragangliomas (mPPGLs) can be difficult to diagnose or predict at initial presentation. Since production of catecholamines from mPPGLs is different from non-metastatic tumors (non-mPPGLs), this study aimed to clarify whether presenting catecholamine-related signs and symptoms (cSS) might also differ. Methods The study included 249 patients, 43 with mPPGL and 206 with non-mPPGL. Clinical data at the time of biochemical diagnosis (i.e. at entry into the study) were used to generate a cumulative score of cSS for each patient. Results Patients with mPPGL were significantly younger (43.3 ± 14 vs. 48.9 ± 16.1 years) and included a lower proportion of females (39.5\% vs. 60.7\%) than patients with non-mPPGLs. Frequencies of signs and symptoms did not differ between the two groups. Patients with mPPGLs had lower (P < 0.001) urinary excretion of epinephrine (3.5 (IQR, 1.9—6.5) µg/day) than those with non-mPPGLs (19.1 (IQR, 4.3—70.2) µg/day). There was no difference in urinary excretion of norepinephrine. In patients with mPPGLs a high cSS score was associated with high urinary excretion of norepinephrine and normetanephrine. In contrast, in patients with non-mPPGLs, a high cSS was associated with high urinary excretion of epinephrine and metanephrine. Conclusion Although presenting signs and symptoms were associated with production of norepinephrine in patients with mPPGLs and of epinephrine in patients with non-mPPGLs, there were no differences in signs and symptoms between the two groups. Therefore, consideration of signs and symptoms does not appear helpful for distinguishing patients with and without mPPGLs.},
  language  = {en}
}
@article{GrabenhenrichReichFischeretal.2014,
  author    = {Grabenhenrich, Linus B. and Reich, Andreas and Fischer, Felix and Zepp, Fred and Forster, Johannes and Schuster, Antje and Bauer, Carl-Peter and Bergmann, Renate L. and Bergmann, Karl E. and Wahn, Ulrich and Keil, Thomas and Lau, Susanne},
  title     = {The Novel 10-Item Asthma Prediction Tool: External Validation in the German MAS Birth Cohort},
  series = {PLOS ONE},
  volume    = {9},
  journal   = {PLOS ONE},
  number    = {12},
  issn      = {1932-6203},
  doi       = {10.1371/journal.pone.0115852},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-114202},
  pages     = {e115852},
  year      = {2014},
  abstract  = {Background: A novel non-invasive asthma prediction tool from the Leicester Cohort, UK, forecasts asthma at age 8 years based on 10 predictors assessed in early childhood, including current respiratory symptoms, eczema, and parental history of asthma. Objective: We aimed to externally validate the proposed asthma prediction method in a German birth cohort. Methods: The MAS-90 study (Multicentre Allergy Study) recorded details on allergic diseases prospectively in about yearly follow-up assessments up to age 20 years in a cohort of 1,314 children born 1990. We replicated the scoring method from the Leicester cohort and assessed prediction, performance and discrimination. The primary outcome was defined as the combination of parent-reported wheeze and asthma drugs (both in last 12 months) at age 8. Sensitivity analyses assessed model performance for outcomes related to asthma up to age 20 years. Results: For 140 children parents reported current wheeze or cough at age 3 years. Score distribution and frequencies of later asthma resembled the Leicester cohort: 9\% vs. 16\% (MAS-90 vs. Leicester) of children at low risk at 3 years had asthma at 8 years, at medium risk 45\% vs. 48\%. Performance of the asthma prediction tool in the MAS-90 cohort was similar (Brier score 0.22 vs. 0.23) and discrimination slightly better than in the original cohort (area under the curve, AUC 0.83 vs. 0.78). Prediction and discrimination were robust against changes of inclusion criteria, scoring and outcome definitions. The secondary outcome 'physicians' diagnosed asthma at 20 years' showed the highest discrimination (AUC 0.89). Conclusion: The novel asthma prediction tool from the Leicester cohort, UK, performed well in another population, a German birth cohort, supporting its use and further development as a simple aid to predict asthma risk in clinical settings.},
  language  = {en}
}
@article{SteinmannPaeleckeHabermannGeinitzetal.2012,
  author    = {Steinmann, Diana and Paelecke-Habermann, Yvonne and Geinitz, Hans and Aschoff, Raimund and Bayerl, Anja and B{\"o}lling, Tobias and Bosch, Elisabeth and Bruns, Frank and Eichenseder-Seiss, Ute and Gerstein, Johanna and Gharbi, Nadine and Hagg, Juliane and Hipp, Matthias and Kleff, Irmgard and M{\"u}ller, Axel and Sch{\"a}fer, Christof and Schleicher, Ursula and Sehlen, Susanne and Theodorou, Marilena and Wypior, Hans-Joachim and Zehentmayr, Franz and van Oorschot, Birgitt and Vordermark, Dirk},
  title     = {Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases},
  series = {BMC Cancer},
  volume    = {12},
  journal   = {BMC Cancer},
  number    = {283},
  doi       = {10.1186/1471-2407-12-283},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135254},
  year      = {2012},
  abstract  = {Background: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information. Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 \%) received whole-brain radiotherapy. QoL was measured with the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months. Results: At 3 months, 88/142 (62 \%) survived. Nine patients were not able to be followed up. 62 patients (70.5 \% of 3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss, drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at 3 months could be reduced compared to pre-treatment (63 \% vs. 37 \%), the score for headaches remained stable. Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy were prognostic of 3-month survival. Conclusions: Moderate deterioration in several QoL domains was predominantly observed three months after start of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain prognostic information.},
  language  = {en}
}
@phdthesis{Scholtka2011,
  author    = {Scholtka, Jacqueline},
  title     = {Symptome und Befund der pulmonalen Sarkoidose. Eine retrospektive Verlaufsbeobachtung},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-72122},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {131 Patienten mit Sarkoidose der Medizinischen Klinik und Poliklinik I in W{\"u}rzburg wurden r{\"u}ckblickend anhand der vorliegenden Krankenakten untersucht. Hierbei wurden insbesondere Daten zu Symptomen, Laboruntersuchungen, Lungenfunktionsuntersuchungen sowie radiologischen Untersuchungen gesammelt und ausgewertet. Es wird ein allgemeiner {\"U}berblick {\"u}ber die H{\"a}ufigkeit der einzelnen Symptombereiche sowie Untersuchungsbefunde gegeben. Des weiteren wird anhand eines Bewertungsscores der Erkrankungsverlauf der Patienten abgebildet.},
  subject      = {Sarkoidose},
  language  = {de}
}
@phdthesis{Lorenc2011,
  author    = {Lorenc, Simone Iris [geb. Lindhof]},
  title     = {Das M{\"u}nchhausen-by-proxy-Syndrom in Deutschland - erste Daten -},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-76941},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Erhebung erster Daten {\"u}ber das Vorliegen des M{\"u}nchhausen-by-proxy-Syndroms, einer besonderen Form der Kindesmisshandlung, in Deutschland. Alle Kinderkliniken in Deutschland wurden im ersten Schritt nach F{\"a}llen und dem {\"u}berblickten Zeitraum gefragt. Im zweiten Schritt folgte ein 23-seitiger Fragebogen mit Angaben u.a. zum Opfer, zu vorliegenden oder geschilderten Symptomen, zur Art des Missbrauchsnachweises, zur verursachenden Person, zum Verhalten der verursachenden Person, zum Partner der verursachenden Person, zu Geschwisterkindern, zu rechtlichen Folgen f{\"u}r die Opfer und die verursachende Person. Dem geschichtlichen Abspann folgte nach Auswertung unserer Daten eine Diskussion im Hinblick auf die derzeitige internationale Datenlage sowie ein Blick in die Zukunft.},
  subject      = {M{\"u}nchhausen-Syndrom der Angeh{\"o}rigen},
  language  = {de}
}